Hoth Therapeutics Stock Fundamentals
| HOTH Stock | USD 0.83 0.01 1.22% |
Hoth Therapeutics fundamentals help investors to digest information that contributes to Hoth Therapeutics' financial success or failures. It also enables traders to predict the movement of Hoth Stock. The fundamental analysis module provides a way to measure Hoth Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hoth Therapeutics stock.
As of now, Hoth Therapeutics' Research Development is increasing as compared to previous years. The Hoth Therapeutics' current Total Operating Expenses is estimated to increase to about 8.4 M, while Interest Income is projected to decrease to 741.95. Hoth | Select Account or Indicator |
Hoth Therapeutics Company Current Valuation Analysis
Hoth Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Hoth Therapeutics Current Valuation | (2.28 M) |
Most of Hoth Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hoth Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Hoth Therapeutics has a Current Valuation of (2.28 Million). This is 100.02% lower than that of the Pharmaceuticals sector and 100.05% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
Hoth Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hoth Therapeutics's current stock value. Our valuation model uses many indicators to compare Hoth Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hoth Therapeutics competition to find correlations between indicators driving Hoth Therapeutics's intrinsic value. More Info.Hoth Therapeutics is rated # 5 in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Hoth Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hoth Therapeutics' earnings, one of the primary drivers of an investment's value.Hoth Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hoth Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics of similar companies.Hoth Therapeutics is currently under evaluation in current valuation category among its peers.
Hoth Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hoth Therapeutics from analyzing Hoth Therapeutics' financial statements. These drivers represent accounts that assess Hoth Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hoth Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 56.7M | 29.3M | 14.7M | 9.3M | 4.9M | 4.7M | |
| Enterprise Value | 55.0M | 26.7M | 6.2M | 2.9M | (4.3M) | (4.1M) |
Hoth Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (2.28 M) | ||||
| Shares Outstanding | 6.9 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 5.30 % | ||||
| Number Of Shares Shorted | 620.78 K | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 0.76 X | ||||
| EBITDA | (153.15 K) | ||||
| Net Income | (7.85 M) | ||||
| Cash And Equivalents | 11.62 M | ||||
| Cash Per Share | 9.02 X | ||||
| Total Debt | 55.16 K | ||||
| Debt To Equity | 2.01 % | ||||
| Current Ratio | 15.74 X | ||||
| Book Value Per Share | 1.09 X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.5 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 5.74 M | ||||
| Total Asset | 9.52 M | ||||
| Retained Earnings | (52.94 M) | ||||
| Working Capital | 8.75 M | ||||
| Current Asset | 448.84 K | ||||
| Current Liabilities | 312.22 K | ||||
| Net Asset | 9.52 M |
About Hoth Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hoth Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 76.9 K | 73 K |
Currently Active Assets on Macroaxis
When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:Check out Hoth Therapeutics Piotroski F Score and Hoth Therapeutics Altman Z Score analysis. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.46) | Return On Equity (0.83) |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.